Kornimate/medical-research-clean huggingface dataset:
association between preoperative hyperglycemia and postoperative delirium in geriatric hip fracture patients

Conditions: Postoperative Delirium; Hip Fractures; Hyperglycemia

Summary: this retrospective study aims to collect electronic medical record data from dandong central hospital spanning from january 2013 to november 2023. the collected data does not contain any personally identifiable information or breach privacy. additionally, this study design does not involve active intervention measures or patient recruitment. the research aims to investigate the correlation between preoperative blood glucose levels in elderly hip fracture patients and postoperative delirium.

a retrospective observational study is planned to explore specific phenomena or associations using electronic medical record data. the collected data does not contain any personally identifiable information or compromise privacy. additionally, this study design does not involve active intervention measures or patient recruitment. the study data is sourced from the electronic medical record system of hospitalized patients and has received approval from the hospital's research center, with ongoing supervision by the hospital's ethics committee. the study aims to investigate the correlation between preoperative blood glucose levels in hip fracture patients and postoperative complications. the retrospective study aims to collect electronic medical record data spanning from january 2013 to november 2023. the data collection process is consistently monitored and verified by the hospital's ethics committee. throughout the study, adherence to the ethical principles outlined in the 1964 helsinki declaration is ensured, and institutional review board (irb) approval has been obtained for all aspects of the research. the study aims to provide valuable evidence-based medicine for clinical practitioners by examining the relationship between preoperative persistent hyperglycemia in elderly hip fracture patients and postoperative delirium. furthermore, it seeks to offer clinical insights for early identification and intervention management of high-risk postoperative delirium patients (pod).

Eligibility criteria:
inclusion criteria: 1) patients who have undergone surgical treatment for hip fractures. exclusion criteria: 1. multiple or pathological hip fractures. 2. emergent surgery. 3. age below 60 years. 4. incomplete electronic medical records or preoperative blood glucose levels were assessed fewer than two times. 5. presence of neurological and psychiatric disorders, except dementia.
study comparing pursestring wound closure vs conventional closure to reverse stoma of colorectal cancer patients

Conditions: Colorectal Cancer; Stoma Closure Technic

Summary: temporary stomas has been performed to reduce complications after colorectal cancer surgery, especially in high-risk anastomosis. different closure technics showed different outcome. the aim of this study is to compare the scar length , surgical site infection and pain score of purse-string wound closure vs conventional closure.


Eligibility criteria:
inclusion criteria: * receiving temporary ostomy because of colorectal cancer at least 3 months ago; * age of≥18 and ≤80 exclusion criteria: * not willing or incapable to comply with all study visits and assessments * evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that puts the patient at high risk for treatment-related complications
effect of device guided breathing on sleeplessness (2brt01)

Conditions: Sleep Initiation and Maintenance Disorders

Summary: the current study is designed to evaluate the effect of device guided breathing (dgb) on sleeplessness. healthy subjects with mild to moderate sleeplessness that wish to improve their sleep quality will be included in this study. the subjects will receive a belt type breathing sensor, download the app on their smartphone, and will be required to perform dgb at their home setting for 2 weeks after a baseline period.

sleeplessness, defined as difficulty in falling asleep or maintaining sleep, is prevalent in about one third of the us population. sleeplessness was found to have negative impact on the quality of life and daily functionality and in its chronic form, was also found to frequently lead to sympathetic over-activity. stress is an important factor in triggering and exacerbating sleeplessness and its symptoms. current methods for alleviating the problem include drugs, modification of sleep habits (also delivered via smartphones), cognitive behavior therapy that includes relaxation techniques such as mindfulness, meditation, and diaphragmatic breathing. breathing pattern modification, as done by device guided breathing (dgb) was found to affect beneficially the cardiovascular system. dgb guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. this is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing breathing pattern modification, as done by dgb was originally implemented in a device called resperate that was cleared by the fda for treating hypertension and stress and its use was supported by multiple clinical trials. however, the direct effect of dgb on sleeplessness has not yet been investigated, dgb was recently implemented in a mobile system that consists of a bluetooth enabled belt-type breathing sensor and an ios mobile application ('app'). the app accumulates continuously breathing-related data and performance measure. the accumulated data are sent to an icloud-based server. the current study is a single center, prospective, randomized, waiting-list-controlled (wlc) clinical trial designed to evaluate the effect of dgb on sleeplessness using the mobile dgb2 system.

Eligibility criteria:
inclusion criteria: 1. healthy with mild to moderate sleeplessness 2. male or female, age 18-65 3. has ipod/ipad or smartphone compatible with the system used in the study 4. has access to internet and email 5. knowledge of english to the level of understanding the app and the sleep-monitor interface. exclusion criteria: 1. known sleep or respiration disorder 2. a serious systemic disease 3. pittsburg insomnia rating scale (pirs_2) \<2 4. pregnant
a study to observe the safety and efficacy of vedolizumab in biologically naive participants with ulcerative colitis (uc) or crohn´s disease (cd)

Conditions: Crohn Disease; Colitis, Ulcerative; Inflammatory Bowel Diseases

Summary: the purpose of this non-interventional study (nis) study is to assess further knowledge on the routine use of entyvio in inflammatory bowel disease therapy, particularly the use in participants with cd and uc naive to biologics.

the drug being tested in this prospective, observational study is called vedolizumab. vedolizumab (entyvio) is being used to treat people who have cd or uc. this study will look in the routine use of vedolizumab in inflammatory bowel disease therapy in participants with cd or uc who did not receive a biologic treatment before. the study will enroll approximately 150 participants. all participants enrolled in this will belong to one observational group: vedolizumab. participants taking vedolizumab as per physician's prescription in routine clinical practice will be observed. this multi-centre trial will be conducted in austria. the overall time to participate in this study is 2 years. participant taking vedolizumab in routine clinical practice will make multiple visits to the clinic at baseline, week 20 and 52. once a participant is switched to subsequent biologic treatment upon failing treatment with vedolizumab, the switching date will be considered as new baseline followed by visits at week 20 and 52.

Eligibility criteria:
inclusion criteria 1 initiating vedolizumab for moderately to severely active uc or cd. exclusion criteria 1. participant is enrolled in a clinical trial in which treatment for uc or cd is managed through a protocol, 2. prior treatment with a biologic agent, 3. any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.

Keywords: drug therapy
alternate-day buprenorphine. phase v - 6

Conditions: Opioid-Related Disorders

Summary: the purpose of this study is to evaluate buprenorphine blockade challenge.


Eligibility criteria:
please contact site for information.
the effect of remote ischemic preconditioning on physical performance and exertional rhabdomyolysis

Conditions: Physical Performance; Rhabdomyolysis

Summary: in order to examine the effect of ripc on skeleton muscle exertional damage and on aerobic and anaerobic physical performances, 30 healthy volunteers will undergo a series of different physical tests twice; once without intervention and a second time with ripc intervention or placebo (false) intervention.

30 healthy civilians volunteers will be recruited and divided randomly into 2 groups: ripc group and control group. the experiment protocol consist 2 series (with a month between them), both series include the described 3 days: day 1 - anthropometry measurements and vo2max test (bruce protocol). day 2 - steps test (heled protocol). day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol). the first series will be performed without applying any intervention and is considered as baseline measurements for both groups. the second series will be performed as follows: a. ripc group: applying ripc exposure (placing a sphygmomanometer on the non-dominant hand and applying pressure of 200 mmhg for 5 min followed by 5 min without pressure x 4 repeats) at the beginning of every meeting. b. control group: with placebo (false) exposure (placing a sphygmomanometer on the non-dominant hand and applying pressure of 100 mmhg for 5 min followed by 5 min without pressure x 4 repeats) at the beginning of every meeting. blood ample, lactic acid and urine sample will be tested at the beginning and end of every meeting (testing for muscle, skeleton and kidney function markers).

Eligibility criteria:
inclusion criteria: * aged 18-30 * healthy civilians volunteers * with no background illnesses * above average fitness exclusion criteria: * known chronic medical illness * routine medication usage * history of rhabdomyolysis * the physician decision
comparitive effects of reciprocal inhibtion and static stretching among female athletes

Conditions: Sports Physical Therapy

Summary: the aim of the study is to determine the comparative effects of reciprocal inhibition and static stretching on serratus anterior muscle on pain, range of motion, and functional ability among female amateur athletes

there is an absence of extensive studies comparing the effects of reciprocal inhibition and static stretching specifically on the serratus anterior muscle among female amateur athletes. while some research exists on the general effects of these techniques, there is a gap in gender-specific studies and their application to amateur athletes. by conducting more detailed research in this area, we can better understand how these affect athletes, their pain levels, range of motion, and overall functional ability. this would provide valuable insights for designing warm-up routines and optimizing performance for female amateur athletes.

Eligibility criteria:
inclusion criteria: * females * ages between 17-30 years * amateur athletes ( badminton, weight lifting, volleyball, tennis) * pain in the upper limb ( moderate pain 5-6 level on nprs scale) * to check serratus anterior ( females with strength test positive and shakiness weakness on pressing or overhead activities ) * overhead range of motion of the shoulder ( those with less than 180 degrees) exclusion criteria: * fractures * musculoskeletal problems ( radiculopathy, myelopathy, inflammatory arthritis) * international athletes * recent surgery thoracic spine

Keywords: reciprocal inhibition static stretching serratus anterior
dose-finding study of hexaminolevulinate (hal) photodynamic therapy (pdt) to treat cervical neoplasia

Conditions: Cervical Intraepithelial Neoplasia

Summary: an effective and safe medical therapy would be most welcome to reduce the need for surgical interventions and related adverse events and psychological impact on patients with cervical cancer precursors. in this clinical trial, the investigators propose to evaluate the efficacy and safety of photodynamic therapy (pdt) using hexaminolevulinate (hal) for mild to moderate-grade cin (grade 1-2).


Eligibility criteria:
inclusion criteria: * patients with ectocervical cin1 or cin2 as verified by local pathology (biopsy) obtained within the last month * satisfactory colposcopy examination including: * visibility of entire transformation zone including the squamocolumnar junction and * visibility of entire lesion margin * negative endocervical os by colposcopy * colposcopical visible lesion at visit 2, before treatment * patients with an average sized uterine cervix (approximately 27mm diameter) suitable for application of the klemcap * age 18 or above * written informed consent signed exclusion criteria: * previous treatment of cin or invasive disease * lesion(s) extending to the vaginal vault * atypical glandular cells (agc) or adenocarcinoma in situ (ais) on cytology, malignant cells on cytology or histology or other suspicion of either micro-invasive or invasive disease * suspicion of endocervical disease on colposcopy * current severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological infection as per colposcopy and clinical examination * undiagnosed vaginal bleeding * history of toxic shock syndrome * known or suspected porphyria * known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate or aminolevulinic acid) * pregnancy, or intention to become pregnant during the study period * nursing * childbirth or miscarriage within six weeks of enrolment * use of heart pacemaker * participation in other clinical studies either concurrently or within the last 30 days * risk of poor protocol compliance. patient participation should be considered with respect to living far away from the hospital, plans for moving to another city/state, frequent travelling, planning to become pregnant, drug abuse/alcoholic, difficult working hours, family obligations, other illness (e.g. psychiatric), etc. * unwillingness to use adequate birth control (not abstinence) from screening until last pdt * patient is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol

Keywords: cin
study on gamma sensory flicker for insomnia

Conditions: Sleep Quality; Sleep Duration; Sleep Onset Latency

Summary: this prospective observational study enrolled adult volunteers for a sleep quality research study through a questionnaire survey distributed via a wechat two-dimensional code from may 2021 to april 2022. participants were exposed to flicker stimulation through a light and sound device for a duration of 8 weeks with daily monitoring.

this prospective observational study enrolled adult volunteers for a sleep quality research study through a questionnaire survey distributed via a wechat two-dimensional code from may 2021 to april 2022. participants were exposed to flicker stimulation through a light and sound device for a duration of 8 weeks with daily monitoring. a total of 37 participants underwent polysomnography (psg) prior to the commencement of the study.

Eligibility criteria:
inclusion criteria: clinical diagnosis of insomnia according to dsm-5 cumulative score of ≥7 on the seven-factor components of the pittsburgh sleep quality index. sleep disturbances manifest at least three times per week. exclusion criteria: secondary insomnia related to other mental disorders substance-induced sleep disorders environmental sleep disorders sleep apnea syndrome. stroke patients insomnia caused by physical diseases, severe ophthalmic diseases brain tumors suspected or confirmed history of alcohol or drug abuse psychoactive drugs pregnancy previous participation in clinical trials within the past three months epilepsy or family history of epilepsy.

Keywords: gamma sensory flicke insomnia sleep quality adherence adverse effect
a preliminary clinical usability study for the recovery force dvt ii cuff

Conditions: Deep Vein Thrombosis; Venous Thrombosis

Summary: a preliminary clinical usability study to assess design, comfort, wearability, and acceptance of recovery force's deep vein thrombosis (dvt) cuff

a single site, observational study will be conducted at the university of southern california (usc) with participants who have and/or have had previous experience with dvt pneumatic cuffs. study staff will examine participants overall experience, product functionality and perceived adherence to recovery force's dvt ii cuff.

Eligibility criteria:
inclusion criteria: * male or female age 18-65 who have had exposure with a dvt cuff on the calf within the last 6 months from a previous or current clinical condition exclusion criteria: -
effect of exercise on spread of the miconozole nitrate ovule in the vagina

Conditions: Health; Vulvovaginal Candidiasis

Summary: this study uses mri to detect the spread of the miconozole nitrate ovule within the vagina. the effect of moderate amounts of physical activity on the spread will be evaluated, and compared to no physical activity.


Eligibility criteria:
inclusion criteria: * not at risk for pregnancy * willing to abstain from intercourse 24 hours prior to mri * regular menstrual cycles (every 23-38 days) * at least 10 weeks from most recent pregnancy outcome and had 2 spontaneous menstrual cycles since * normal pap smear within previous 12 months * negative test for yeast, bacterial vaginosis and trichomonas * not allergic to any component of the formulation * no contraindications to mri * not participated in another investigational trial within 30 days * no history of condition, or finding on exam, that, in the opinion of the investigator, would make participation unsafe for the volunteer or complicate interpretation of the data
tucatinib, trastuzumab, ramucirumab, and paclitaxel versus paclitaxel and ramucirumab in previously treated her2+ gastroesophageal cancer

Conditions: Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma

Summary: this study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat her2-positive (her2+) cancer of the gut (stomach or gastroesophageal cancer). this study will also look at what side effects happen when participants take this combination of drugs. a side effect is anything the drug does other than treating cancer. study treatment will be given in 28-day cycles. in the phase 2 part of the trial, participants and their doctors will know what drugs are being given (open-label). in the phase 3 part, the study is "blinded." this means that participants, their doctor, and the study sponsor will not know which drugs are being given.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of locally-advanced unresectable or metastatic her2+ gastric or gastroesophageal junction adenocarcinoma (gec) * her2+ disease documented since progression of the most recent line of systemic therapy, as follows: * phase 2 paclitaxel dose optimization stage: * her2 amplification in a blood-based ngs assay performed at a central laboratory, or * her2 overexpression/amplification immunohistochemistry (ihc) and in situ hybridization (ish) (ihc3+ or ihc2+/ish+) assay of a tumor tissue sample * phase 2 dose expansion stage: * cohort 2a: her2 amplification in a blood-based ngs assay performed at a central laboratory * cohort 2b: no her2 amplification by blood-based ngs assay, but her2 overexpression/amplification by ihc and ish (ihc3+ or ihc2+/ish+) assay of a tumor tissue sample * phase 3: her2 amplification in a blood-based ngs assay performed at a central laboratory * history of prior treatment with a her2-directed antibody * progressive disease during or after first-line therapy for locally-advanced unresectable or metastatic gec * phase 2: measurable disease according to recist version 1.1 * phase 3: measurable or non-measurable disease according to recist version 1.1 * eastern cooperative oncology group (ecog) performance status score of 0 or 1 * life expectancy of at least 3 months, in the opinion of the investigator exclusion criteria: * subjects with squamous cell or undifferentiated gec * having received more than 1 line of prior systemic therapy for locally-advanced unresectable or metastatic disease * having received taxanes ≤12 months prior to enrollment, prior treatment with ramucirumab, or prior treatment with tucatinib, lapatinib, neratinib, afatinib, or any other investigational anti-her2 and/or anti-egfr tyrosine kinase inhibitor, or with t-dm1, t-dxd, or any other her2-directed antibody-drug conjugate * phase 2 paclitaxel dose optimization stage only: history of prior partial or total gastrectomy * unable to swallow pills

Keywords: her2+ her2-positive gea gec gej seattle genetics
parental education on passive smoke exposure and respiratory diseases in infants

Conditions: Tobacco Smoke Pollution

Summary: parental smoking is associated with increased frequency of respiratory diseases including hospitalizations in infants. study hypothesis: parental education regarding the association between parental smoking and respiratory diseases in the infant, and guidance on ways to decrease smoke exposure by the infant, provided shortly after the infant is born, will decrease infants' morbidity.

mothers who are in maternity ward following birth will fill a questionnaire regarding smoking habits. parents will be divided into non-smokers and smokers. half of the smoking mothers will receive guidance regarding the association between parents smoking and respiratory diseases in the infant. they will also get ideas on how to reduce smoke exposure by their infant. 3 months and 1 year later all parents will be contacted by phone and asked about their children's health.

Eligibility criteria:
inclusion criteria: * infants born at asaf harofeh medical center * infants born at \>35w gestational age exclusion criteria: * infants requiring any supportive treatment (supplemental o2, fluids, glucose, antibiotics)